Nurix Therapeutics (NASDAQ:NRIX) Receives “Buy” Rating from BTIG Research

BTIG Research reiterated their buy rating on shares of Nurix Therapeutics (NASDAQ:NRIX) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $32.00 price objective on the stock.

NRIX has been the topic of a number of other reports. Needham & Company LLC reissued a “buy” rating and issued a $34.00 price target on shares of Nurix Therapeutics in a research note on Monday, June 15th. Wells Fargo & Company cut shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and lowered their price objective for the stock from $28.00 to $25.00 in a research report on Monday, June 8th. Robert W. Baird lifted their target price on shares of Nurix Therapeutics from $26.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Oppenheimer initiated coverage on Nurix Therapeutics in a research report on Monday, June 29th. They issued an “outperform” rating and a $28.00 target price on the stock. Finally, Truist Financial boosted their target price on Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.77.

Nurix Therapeutics Trading Down 6.6%

Shares of NASDAQ:NRIX opened at $23.06 on Friday. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -7.30 and a beta of 1.80. Nurix Therapeutics has a 12-month low of $8.19 and a 12-month high of $25.08. The business has a 50-day moving average price of $18.44 and a 200 day moving average price of $17.37.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 73.57%. The company had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. As a group, equities research analysts predict that Nurix Therapeutics will post -2.88 earnings per share for the current fiscal year.

Insider Activity

In other Nurix Therapeutics news, CFO Houte Hans Van sold 14,055 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total value of $233,313.00. Following the sale, the chief financial officer owned 37,592 shares of the company’s stock, valued at $624,027.20. This trade represents a 27.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.00, for a total value of $107,880.00. Following the completion of the transaction, the insider owned 115,005 shares of the company’s stock, valued at $2,300,100. The trade was a 4.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 25,051 shares of company stock worth $434,466. 6.70% of the stock is owned by company insiders.

Institutional Trading of Nurix Therapeutics

Several hedge funds have recently added to or reduced their stakes in NRIX. Vanguard Group Inc. grew its holdings in Nurix Therapeutics by 32.5% during the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock worth $112,862,000 after acquiring an additional 1,460,736 shares in the last quarter. General Atlantic L.P. purchased a new stake in shares of Nurix Therapeutics during the 4th quarter worth $92,899,000. Morgan Stanley lifted its position in shares of Nurix Therapeutics by 115.9% during the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock worth $92,594,000 after purchasing an additional 2,620,323 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Nurix Therapeutics by 35.0% during the fourth quarter. Vestal Point Capital LP now owns 4,690,000 shares of the company’s stock worth $88,969,000 after purchasing an additional 1,215,000 shares in the last quarter. Finally, Baker BROS. Advisors LP grew its stake in shares of Nurix Therapeutics by 20.0% during the fourth quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock worth $88,373,000 after purchasing an additional 776,431 shares in the last quarter.

Key Stories Impacting Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Roche collaboration news was a major catalyst: Nurix said it entered a global partnership for bexobrutideg with potential total payments of up to $2.3 billion, including a $700 million upfront payment. Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: Royal Bank of Canada raised its price target on Nurix Therapeutics from $30 to $33 and reiterated an outperform rating, signaling confidence in upside from current levels.
• Positive Sentiment: Stifel Nicolaus lifted its target from $34 to $40 and maintained a buy rating, while Needham and BTIG also reaffirmed buy ratings with targets of $34 and $32, respectively, adding to the bullish analyst tone.
• Neutral Sentiment: Nurix reported second-quarter 2026 results with an EPS loss of $0.81 and revenue of $9.04 million, both below estimates, which kept focus on the company’s pipeline and partnership potential rather than near-term fundamentals. Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Negative Sentiment: The earnings miss may cap enthusiasm somewhat, as the company posted a wider loss than expected and revenue came in well below consensus. Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.